Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma

JACKSONVILLE, Fla. — A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell t herapy). The study is published in Cancer Discovery. "CAR-T cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for patients who have relapsed or those who have not responded…
Source: Mayo Clinic Research News - Category: Research Source Type: news